Cargando…
Characteristics of CD5-positive diffuse large B-cell lymphoma among Koreans: High incidence of BCL2 and MYC double-expressors
Aberrant expression of CD5 has been reported in 5–10% of diffuse large B-cell lymphomas (DLBCLs). CD5+ DLBCL had been recognized as an aggressive immunophenotypic subgroup of DLBCL in the 2008 WHO classification of haematolymphoid neoplasm; however, it was eliminated from the list of subgroups of DL...
Autores principales: | Na, Hee Young, Choe, Ji-Young, Shin, Sun Ah, Kim, Hyun-Jung, Han, Jae Ho, Kim, Hee Kyung, Oh, So Hee, Kim, Ji Eun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6808439/ https://www.ncbi.nlm.nih.gov/pubmed/31644584 http://dx.doi.org/10.1371/journal.pone.0224247 |
Ejemplares similares
-
Upregulation of fatty acid synthase in MYC and BCL-2 double-expressor lymphoma
por: Zhong, Xing, et al.
Publicado: (2021) -
Prognostic impact of diffuse large B-cell lymphoma with extra copies of MYC, BCL2 and/or BCL6: comparison with double/triple hit lymphoma and double expressor lymphoma
por: Huang, Sixia, et al.
Publicado: (2019) -
Double-Expressor Phenotype (BCL-2/c-MYC Co-expression) of Diffuse Large B-Cell Lymphoma and Its Clinicopathological Correlation
por: Hashmi, Atif A, et al.
Publicado: (2021) -
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma
por: Melchor, Javier, et al.
Publicado: (2023) -
Enhanced lipid metabolism confers the immunosuppressive tumor microenvironment in CD5-positive non-MYC/BCL2 double expressor lymphoma
por: Liu, Meng-Ke, et al.
Publicado: (2022)